Reversing LCA?
Gene therapy that corrects a mutation in NPHP5 shows promise in a canine model of Leber congenital amaurosis
Researchers have been developing a gene therapy for a form of Leber congenital amaurosis (LCA) caused by a mutation in the NPHP5 gene. The mutation leads to rod cell degeneration and death – and an almost identical disease phenotype is seen in dogs with a naturally occurring mutation in the same gene. After injecting AAV viral vectors carrying the normal version of the gene into the (single) eyes of nine five-week-old dogs, the team observed stable restoration of photoreceptor structure, function, and vision – the latter indicated by performance improvements in an obstacle-avoidance course six months after treatment (1).
“What’s so appealing and so exciting here is that we’re not just stopping a disease process, we’re actually reverting a photoreceptor cell that is abnormal to become normal and function,” said William Beltran, study author and a professor of ophthalmology at Penn. Ongoing studies lead the researchers to believe that the treatment may be effective even at later stages of the disease.
- GD Aguirre et al., Mol Ther, [Online ahead of print] (2021). PMID: 33781914.
Having edited several technical publications over the last decade, I crossed paths with quite a few of Texere's current team members, and I only ever heard them sing the company's praises. When an opportunity arose to join Texere, I jumped at the chance! With a background in literature, I love the company's ethos of producing genuinely engaging content, and the fact that it is so well received by our readers makes it even more rewarding.
